Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The Generic pharmaceuticals Market size worth USD 766.5 Billion at 8.8% CAGR over the forecast period 2023-2032. The Generic Pharmaceuticals Market is characterized by a multitude of factors that collectively influence its growth and dynamics. One of the underlying factors is patients' expectations of quality medicines as well as financial availability. With international healthcare costs growing, generic products are a more cost-effective alternative to branded similar products. This is why both the healthcare provider and the consumer go for generic products. That to the fact that generics have substantial economic benefit is especially true in areas where health and the affordability issues become the most important challenges to overcome.
Period of drying up of branded drugs patents is considered as the main factor that influence the growth of generic pharmaceuticals. Upon the expiration of the patents, they provide an opportunity for the generics producers to make and market drugs with similar composition and effects with the originals. The expiry of this patent, frequently called the "patent cliff," causes more lots of competition and therefore more drugs produced by generic manufacturers thus a range of drugs becomes cheaper medicaments for consumers.
As global diligence of the chronic disorder increases, wide use of common medications in the process of managing chronic illness also becomes a challenge. With the steady rising rate of incidence for chronic diseases including cardiovascular disease, diabetes, and respiratory ailments, there is also a subsequent increase in demand for cheap medicines. Generic counterparts of medicines, which are utilized frequently in case of chronic diseases, allow patients to obtain accessible treatment while maintaining superior adherence and good health conditions within the society.
As for the market factors, they have the healthcare systems and payers' preferences as a part of their agenda. With the growing demand for healthcare worldwide, public, and private healthcare systems are increasingly favoring the use of off-patent drugs, which has the net effect of reducing costs and achieving cost-effectiveness. The provision of generic drugs for the formularies and single prescription plans results in healthcare specialists prescribing and dispensing generic equivalents, which, in turn, lead to market growth.
To this, addition a growing popularity of the term “generic biosimilars” shows itself as one of the key determinant of generic market. To this end, besides the advanced biologics, newer biosimilars, to replace older biologics, are frequently approved. Brand-name biologics are generally the most expensive types of medicines, and so, their biosimilars are increasingly being adopted and utilized as substitutes. This is because generics are cheaper, and so, they benefit the development of the entire generic pharmaceutical market.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Market Size Value In 2022 | USD 358.8 Billion |
| Market Size Value In 2023 | USD 390.37 Billion |
| Growth Rate | 8.80% (2023-2032) |
Generic Pharmaceuticals Market Highlights:
Generic Drugs Overview
Generic Drugs Market size was valued at USD 410.60 billion in 2023. The Generic Drugs Market industry is projected to grow from USD 437.90 billion in 2024 to USD 874.36 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.85% during the forecast period (2024 - 2032).
Increasing incidences of chronic diseases across the globe and rising strategic initiatives by market players are the major factors driving the growth of the global generic drug market. However, voluntary product recalls from market players are expected to hamper the growth of the global market. Nevertheless, investment in research and development (R&D) for generic drugs is anticipated to create lucrative opportunities for the market.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Generic Drugs Trends
Increasing incidences of chronic diseases across the globe fuels market growth
The escalating prevalence of chronic diseases worldwide is acting as a significant catalyst for the expansion of the global generic drug market. With conditions like cancer, neurology, cardiovascular diseases, inflammatory diseases, and others on the rise, there's an amplified demand for cost-effective treatment options, compelling patients and healthcare providers to turn towards generic medications. Generic drugs, being bioequivalent to their brand-name counterparts but more affordable, offer a viable solution for managing chronic illnesses without burdening healthcare budgets. This burgeoning demand for generics is not only driven by patients seeking affordable therapies but also by healthcare systems and governments striving to contain healthcare expenditure while ensuring widespread access to essential medications. Additionally, the increasing incidence of cardiovascular conditions worldwide is burgeoning the growth of the generic drugs market. As per the American Heart Association, there were nearly 244.1 million people living with ischemic heart disease (IHD) in 2020. Also, in May 2023, the Centers for Disease Control and Prevention reported that 805,000 people in the US have heart attacks every year. Also, the rising cases of inflammatory diseases such as rheumatoid arthritis and bowel inflammatory diseases across the globe are boosting the growth of the generic drugs market.
Generic Drugs Segment Insights
Generic Drugs Type Insights
The Generic Drugs Market segmentation, based on type, includes simple generics and super generics. The simple generics segment held the majority share in the market in 2023. Simple generic drugs are widely prescribed due to its easy availability. Furthermore, the rise in prevalence of chronic diseases such as hypertension, asthma and COPD will further drive the simple generics segment.
Generic Drugs Brand Insights
The Generic Drugs Market segmentation, based on brand, includes pure generic and branded generic. The pure generic segment held the largest market share in 2023 and the branded generic is the fastest-growing segment during the forecast period. Branded generics are marketed under a brand name chosen by the manufacturer. They may be perceived as having higher quality or better efficacy compared to pure generics due to branding and marketing efforts.
Figure 2: Generic Drugs Market, by Brand, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Generic Drugs Indication Insights
The Generic Drugs Market segmentation, based on indication, includes central nervous system (CNS), cardiovascular, urology, oncology, respiratory, and others. The oncology segment held the largest market share in 2023, and cardiovascular segment is the fastest-growing segment during the forecast period i.e., 2024-2032. Oncology drugs are essential for treating various types of cancer, including breast cancer, lung cancer, prostate cancer, leukemia, and lymphoma. Furthermore, rise in cancer cases and growing research-related activities in the pharmaceutical industry will drive the segment growth.
The Generic Drugs Market segmentation, based on route of administration, includes oral, topical, parenteral, and others. The oral segment held the largest market share in 2023 and parenteral is the fastest-growing segment during the forecast period i.e., 2024-2032. Oral dosage form has advantages such as ease of administration and no nursing requirements which leads to higher patient acceptability and compliance and efficacy to fight against disease such as pneumonia and respiratory infections.
The Generic Drugs Market segmentation, based on distribution channel, includes hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment held the largest market share in 2023 and online pharmacy is the fastest-growing segment during the forecast period i.e., 2024-2032. Online pharmacies provide comfort, flexibility, and convenience for the purchase of medications.
Generic Drugs Regional Insights
By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. The North America Generic Drugs market is experiencing significant growth, driven by factors such as increasing demand for Generic Drugs at hospitals and medical settings, advancements in technology, and the rising prevalence of chronic diseases.
Further, the major countries will be study are US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Figure 3: GENERIC DRUGS MARKET BY REGION 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Generic Drugs market accounted for the second-largest market share due to well-established healthcare infrastructure, coupled with collaborations and partnerships between industry players, research organizations and healthcare providers, drives the market. Furthermore, the Germany Generic Drugs provider attributed to hold the largest market share, and the France Generic Drugs providers is projected be the fastest growing market in the Europe region.
The Asia-Pacific Generic Drugs market is expected to be the fastest growing from 2023 to 2032 due to occurrence of chronic medical disorders, such as cancer, diabetes, and cardiovascular diseases, increasing healthcare expenditure and investments in research and development activities. Moreover, China Generic Drugs accounted to hold the largest market share, and the India Generic Drugs is projected to be the fastest growing market in the Asia-Pacific region.
Generic Drugs Key Market Players & Competitive Insights
The Generic Drugs Market is distinguished by the presence of numerous global, regional, and local players catering to the generic drugs. Furthermore, the increasing prevalence of chronic diseases and the rising strategic initiatives associated with generic medicine across the globe is further driving the growth of Generic Drugs Market during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products and signing contracts and agreements to broaden their reach. For instance, in February 2023, The US FDA approved generic lenidomide capsules manufactured by Sun Pharma. 2.5 mg, 20 mg, and tentative approval for 10 mg, 15 mg, and 25 mg. Revlimid Capsules, 5 mg, 10 mg, 15 mg, 25 mg, and 2.5 mg, 20 mg are used as the reference product for each product approval. Cancers of different kinds are treated with lenidomide. It functions by inhibiting or halting the growth of cancerous cells. Additionally, it is used to treat anemia in people with certain bone marrow/blood abnormalities (myelodysplastic syndromes, or MDS).
Sun Pharmaceutical Industries Ltd. (India) is one of India’s top pharmaceutical companies. It is the world’s fourth-largest generic pharmaceutical company. It delivers high-quality and reasonable medicines trusted by customers in over 150 countries globally. The company also has a specialty products portfolio that contains ten specialty products, out of which five are in the market, and three are likely to be commercialized soon. It has products for various leading therapeutic areas such as diabetes, oncology, pain, autoimmune diseases, respiratory diseases, antibiotics and vaccines, cardiovascular, HIV, mental health, antivirals, and others. It also conducts business in Western Europe, Canada, Australia, New Zealand, China, and Japan. Moreover, South Africa, Brazil, Mexico, Russia, and Romania are some of our most significant emerging markets.
Moreover, In February 2023, The US FDA approved generic lenidomide capsules manufactured by Sun Pharma. 2.5 mg, 20 mg, and tentative approval for 10 mg, 15 mg, and 25 mg. Revlimid Capsules, 5 mg, 10 mg, 15 mg, 25 mg, and 2.5 mg, 20 mg are used as the reference product for each product approval. Cancers of different kinds are treated with lenidomide. It functions by inhibiting or halting the growth of cancerous cells. Additionally, it is used to treat anemia in people with certain bone marrow/blood abnormalities (myelodysplastic syndromes, or MDS).
Key Companies in the Generic Drugs market includes.
- Sun Pharmaceutical Industries Ltd. (India)
- Lupin Pharmaceuticals, Inc. (India)
- Endo International plc (Ireland)
- Aurobindo Pharma (India)
- Aspen Holdings (South Africa)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- Viatris Inc. (US)
- Cipla ltd. (India)
- Fresenius SE & Co. KGaA (Germany)
- Novartis AG (Switzerland)
Global Generic Drugs Industry Developments
- In March 2024, Par Pharmaceutical, Inc., an operating subsidiary of Endo International plc, introduced a generic version of the ibuprofen-famotidine pills a generic version of Amgen's (US) (formerly Horizon Therapeutics) DUEXIS.
- In February 2024, Fresenius Kabi announced the launch of Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan, for use in treating several forms of cancer.
- In February 2024, Cipla ltd. has been approved by the Central Drugs Standard Control Organisation (CDSCO) to market plazomicin, an antibiotic, in India for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis (kidney infection).
Generic Drugs Segmentation
Generic Drugs Type Outlook
- Simple Generics
- Super Generics
Generic Drugs Brand Outlook
- Pure Generic
- Branded Generic
Generic Drugs Indication Outlook
- Central Nervous System (CNS)
- Cardiovascular
- Urology
- Oncology
- Respiratory
- Others
Generic Drugs Route of Administration Outlook
- Oral
- Topical
- Parenteral
- Others
Generic Drugs Distribution Channel Outlook
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Generic Drugs Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
